Key result
Kansuinine A improved glucose and insulin tolerance and reduced pancreatic β-cell apoptosis in ApoE -/- mice, and mitigated AC3RL-induced apoptosis in rat β-cells by inhibiting oxidative stress.
Why the study?
Dyslipidemia exacerbates pancreatic beta-cell apoptosis, heightening the risk of T2DM, but the protective effects and mechanism of kansuinine A against apolipoprotein C3-rich LDL-induced apoptosis were unknown.
Does Kansuinine A attenuate apolipoprotein C3-rich low-density lipoprotein-induced pancreatic β-cell apoptosis in ApoE -/- mice and rat pancreatic β-cells?
Does Kansuinine A attenuate apolipoprotein C3-rich low-density lipoprotein-induced pancreatic β-cell apoptosis in ApoE -/- mice and rat pancreatic β-cells?
Kansuinine A attenuates dyslipidemia-induced pancreatic β-cell apoptosis and dysfunction through oxidative stress inhibition, suggesting potential as an intervention for dyslipidemia-driven diabetes.
Dyslipidemia exacerbates pancreatic β-cell apoptosis, heightening the risk of type 2 diabetes (T2DM). Kansuinine A (KA), a diterpene from Euphorbia roots, exhibits antiapoptotic properties, suggestive of its therapeutic potential against T2DM. In this study, we evaluated the protective effects of KA against apolipoprotein C3 (ApoC3)-rich low-density lipoprotein (LDL) (AC3RL)-induced β-cell apoptosis and its underlying mechanism of action. ApoE −/− mice fed a high-fat diet and treated with KA demonstrated improved glucose and insulin tolerance, enhanced antioxidant capacity, and reduced pancreatic β-cell apoptosis. In rat pancreatic β-cells (RIN-m5F) exposed to AC3RL, KA significantly improved cell viability, suppressed oxidative stress, and mitigated apoptosis by downregulating lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expression and inhibiting the IκB kinase β (IKKβ)/Inhibitor of κB alpha (IκB⍺)/Nuclear Factor kappa B(NF-κB) signaling pathway. Molecular docking and pathway analyses revealed the interactions of KA with key targets involved in oxidative stress and apoptosis. These findings highlight the ability of KA to counteract AC3RL-induced β-cell dysfunction, offering promise as a potential intervention for dyslipidemia-driven diabetes.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2025) studied Type 2 diabetes / dyslipidemia-driven pancreatic β-cell apoptosis. Kansuinine A vs. Control / Vehicle was evaluated on Pancreatic β-cell apoptosis, glucose and insulin tolerance, and oxidative stress. Kansuinine A improved glucose and insulin tolerance and reduced pancreatic β-cell apoptosis in ApoE -/- mice, and mitigated AC3RL-induced apoptosis in rat β-cells by inhibiting oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: